Although previous studies have shown that sICs, such as sPD‐1, remain stable or increase after certain treatments, such as radiotherapy, anti‐EGFR therapy, or immunotherapy, and is associated with better prognosis in tumor patients,24, 25, 26 these treatments are not completely curative and the tumor microenvironment still persists during treatment. This evidence concerns the gene EGFR and neoplasm.